Acadian Asset Management LLC decreased its stake in shares of Viemed Healthcare, Inc. (NASDAQ:VMD) by 0.5% during the first quarter, Holdings Channel reports. The firm owned 1,549,206 shares of the company’s stock after selling 7,481 shares during the quarter. Acadian Asset Management LLC’s holdings in Viemed Healthcare were worth $15,755,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently modified their holdings of the company. PCJ Investment Counsel Ltd. lifted its position in Viemed Healthcare by 30.2% during the fourth quarter. PCJ Investment Counsel Ltd. now owns 175,730 shares of the company’s stock valued at $1,374,000 after purchasing an additional 40,750 shares during the period. Cove Street Capital LLC raised its position in Viemed Healthcare by 52.1% in the fourth quarter. Cove Street Capital LLC now owns 847,931 shares of the company’s stock worth $6,580,000 after acquiring an additional 290,515 shares during the period. Oppenheimer Asset Management Inc. raised its position in Viemed Healthcare by 34.3% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 20,836 shares of the company’s stock worth $162,000 after acquiring an additional 5,316 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Viemed Healthcare by 135.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,259 shares of the company’s stock worth $94,000 after acquiring an additional 5,319 shares during the period. Finally, Credit Suisse AG raised its position in Viemed Healthcare by 141.8% in the fourth quarter. Credit Suisse AG now owns 48,924 shares of the company’s stock worth $379,000 after acquiring an additional 28,691 shares during the period. Institutional investors own 51.10% of the company’s stock.
Several research analysts have weighed in on VMD shares. Royal Bank of Canada started coverage on shares of Viemed Healthcare in a research report on Friday, March 5th. They issued an “outperform” rating and a $13.00 price target on the stock. TheStreet upgraded shares of Viemed Healthcare from a “c” rating to a “b+” rating in a research report on Monday, March 8th. Finally, Zacks Investment Research downgraded shares of Viemed Healthcare from a “hold” rating to a “sell” rating in a research report on Friday, May 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. Viemed Healthcare has an average rating of “Hold” and a consensus target price of $12.33.
Viemed Healthcare (NASDAQ:VMD) last announced its quarterly earnings data on Monday, May 3rd. The company reported $0.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.01. The firm had revenue of $28.42 million for the quarter, compared to the consensus estimate of $29.00 million. Viemed Healthcare had a net margin of 21.32% and a return on equity of 37.21%. As a group, equities analysts expect that Viemed Healthcare, Inc. will post 0.25 earnings per share for the current year.
Viemed Healthcare Profile
Viemed Healthcare, Inc, through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services.
Recommended Story: What defines an oversold asset?
Want to see what other hedge funds are holding VMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viemed Healthcare, Inc. (NASDAQ:VMD).
Receive News & Ratings for Viemed Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viemed Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.